Decibel Therapeutics announced the appointment of Matthew Kapusta to its Board of Directors. Matthew Kapusta has 25 years of experience in the life sciences industry and currently serves as Chief Executive fficer and Director of uniQure, a global gene therapy company. Under his leadership, uniQure successfully developed the world's first approved gene therapy for people living with hemophilia B. Prior to joining uniQure, Mr. Kapusta held executive roles at AngioDynamics and Smith & Nephew. Mr. Kapusta's career also includes more than a decade of investment banking experience where he focused on mergers, acquisitions and corporate finance transactions for emerging life sciences companies. Mr. Kapusta holds a Master of Business Administration from New York University'sStern School of Business and a Bachelor of Business Administration from University of Michigan'sRoss School of Business, and he
previously earned a Certified Public Accountant license in 1996 while at Ernst & Young.